Acutaas Chemicals Q1 FY27 Revenue Jumps 59.1% YoY to ₹3,297 Million
Acutaas Chemicals reported Q1 FY27 revenue of ₹3,297 million (329.7 crore), a 59.1% YoY increase. EBITDA surged 122.1% to ₹1,131 million (113.1 crore), and PAT rose 70.4% to ₹750 million (75 crore). The company projects 25% revenue growth for the full year with stable margins.
Significant financial performance improvements and positive future outlook are likely to have a high impact on investor perception and company valuation.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, exceeding expectations and demonstrating positive business momentum. Management commentary also expresses confidence in future growth.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has released its investor presentation for the first quarter ended June 30, 2026. The company reported a significant year-on-year revenue growth of 59.1%, reaching ₹3,297 million (329.7 crore) for Q1 FY27. EBITDA saw a substantial increase of 122.1% to ₹1,131 million (113.1 crore), and Profit After Tax (PAT) grew by 70.4% to ₹750 million (75 crore).
Executive Chairman and Managing Director, Mr. Naresh Patel, commented on the strong start to the fiscal year, attributing the revenue growth to business model agility and timely customer delivery. He also highlighted the company's recent certifications as a Great Place to Work and Responsible Care certification from the Indian Chemical Council, emphasizing their commitment to responsible and sustainable growth. The company remains confident in achieving its full-year revenue growth target of 25% with stable margins.
The P&L statement for Q1 FY27 shows Revenue from Operations at ₹3,297 million, up from ₹2,072 million in Q1 FY26. Gross Profit increased by 73.0% to ₹1,909 million, and Gross Margin improved to 57.9% from 53.2%. EBITDA margin expanded to 34.3% from 24.6%, while PAT margin increased to 22.7% from 21.2%. The company also presented its financial performance over the years, showcasing consistent growth in revenue and PAT, with a CAGR of 31.0% for Advance Intermediates Chemicals from FY20-25.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.